Literature DB >> 25972518

Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Gary Wong1, Gary P Kobinger2.   

Abstract

The 2014-2015 outbreak of Ebola virus (EBOV), originating from Guinea, is now responsible for the infection of >20,000 people in 9 countries. Whereas past filovirus outbreaks in sub-Saharan Africa have been rapidly brought under control with comparably few cases, this outbreak has been particularly resistant to containment efforts. Both the general population and primary health care workers have been affected by this outbreak, with hundreds of doctors and nurses being infected in the line of duty. In the absence of approved therapeutics, several caregivers have turned to investigational new drugs as well as experimental therapies in an effort to save lives. This review aims to summarize the candidates currently under consideration for postexposure use in infected patients during the largest EBOV outbreak in history.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25972518      PMCID: PMC4429225          DOI: 10.1128/CMR.00014-15

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  72 in total

1.  Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication.

Authors:  C N Chang; S L Doong; J H Zhou; J W Beach; L S Jeong; C K Chu; C H Tsai; Y C Cheng; D Liotta; R Schinazi
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

2.  Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.

Authors:  Fernando J Bravo; David I Bernstein; James R Beadle; Karl Y Hostetler; Rhonda D Cardin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

4.  Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Authors:  James Pettitt; Larry Zeitlin; Do H Kim; Cara Working; Joshua C Johnson; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael H Pauly; Kevin J Whaley; Michael F Ingram; Ashley Zovanyi; Megan Heinrich; Ashley Piper; Justine Zelko; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

5.  Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.

Authors:  Peter B Jahrling; Joan B Geisbert; James R Swearengen; Thomas Larsen; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

6.  [Intralesional treatment of classical Kaposi sarcoma with interferon-alpha].

Authors:  A Hauschild; C Petres-Dunsche
Journal:  Hautarzt       Date:  1992-12       Impact factor: 0.751

7.  FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Authors:  Lisa M Johansen; Jennifer M Brannan; Sue E Delos; Charles J Shoemaker; Andrea Stossel; Calli Lear; Benjamin G Hoffstrom; Lisa Evans Dewald; Kathryn L Schornberg; Corinne Scully; Joseph Lehár; Lisa E Hensley; Judith M White; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-06-19       Impact factor: 17.956

8.  Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

Authors:  H Green; D M Gibb; A S Walker; D Pillay; K Butler; F Candeias; G Castelli-Gattinara; A Compagnucci; M Della Negra; A de Rossi; C Feiterna-Sperling; C Giaquinto; L Harper; J Levy; Y Saidi; U Wintergerst
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

9.  Infectious disease: tough choices to reduce Ebola transmission.

Authors:  Christopher J M Whitty; Jeremy Farrar; Neil Ferguson; W John Edmunds; Peter Piot; Melissa Leach; Sally C Davies
Journal:  Nature       Date:  2014-11-13       Impact factor: 49.962

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  23 in total

1.  Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Authors:  Anna Z Wec; Andrew S Herbert; Charles D Murin; Elisabeth K Nyakatura; Dafna M Abelson; J Maximilian Fels; Shihua He; Rebekah M James; Marc-Antoine de La Vega; Wenjun Zhu; Russell R Bakken; Eileen Goodwin; Hannah L Turner; Rohit K Jangra; Larry Zeitlin; Xiangguo Qiu; Jonathan R Lai; Laura M Walker; Andrew B Ward; John M Dye; Kartik Chandran; Zachary A Bornholdt
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

Review 2.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Two-mAb cocktail protects macaques against the Makona variant of Ebola virus.

Authors:  Xiangguo Qiu; Jonathan Audet; Ming Lv; Shihua He; Gary Wong; Haiyan Wei; Longlong Luo; Lisa Fernando; Andrea Kroeker; Hugues Fausther Bovendo; Alexander Bello; Feng Li; Pei Ye; Michael Jacobs; Giuseppe Ippolito; Erica Ollmann Saphire; Shengli Bi; Beifen Shen; George F Gao; Larry Zeitlin; Jiannan Feng; Boyan Zhang; Gary P Kobinger
Journal:  Sci Transl Med       Date:  2016-03-09       Impact factor: 17.956

4.  Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.

Authors:  Lorena R Braid; Wei-Gang Hu; John E Davies; Les P Nagata
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

5.  Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection.

Authors:  Xiangguo Qiu; Andrea Kroeker; Shihua He; Robert Kozak; Jonathan Audet; Majambu Mbikay; Michel Chrétien
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

6.  Antiviral activity of quercetin-3-β-O-D-glucoside against Zika virus infection.

Authors:  Gary Wong; Shihua He; Vinayakumar Siragam; Yuhai Bi; Majambu Mbikay; Michel Chretien; Xiangguo Qiu
Journal:  Virol Sin       Date:  2017-12       Impact factor: 4.327

Review 7.  Biodefence research two decades on: worth the investment?

Authors:  Carrie M Long; Andrea Marzi
Journal:  Lancet Infect Dis       Date:  2021-08       Impact factor: 71.421

8.  Prognostic Analysis of Patients with Ebola Virus Disease.

Authors:  Xin Zhang; Yihui Rong; Lijian Sun; Liming Liu; Haibin Su; Jian Zhang; Guangju Teng; Ning Du; Haoyang Chen; Yuan Fang; Wei Zhan; Alex B J Kanu; Sheku M Koroma; Bo Jin; Zhe Xu; Haihan Song
Journal:  PLoS Negl Trop Dis       Date:  2015-09-23

9.  Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection.

Authors:  Xuexing Zheng; Gary Wong; Yongkun Zhao; Hualei Wang; Shihua He; Yuhai Bi; Weijin Chen; Hongli Jin; Weiwei Gai; Di Chu; Zengguo Cao; Chong Wang; Quanshui Fan; Hang Chi; Yuwei Gao; Tiecheng Wang; Na Feng; Feihu Yan; Geng Huang; Ying Zheng; Nan Li; Yuetao Li; Jun Qian; Yong Zou; Gary Kobinger; George Fu Gao; Xiangguo Qiu; Songtao Yang; Xianzhu Xia
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.379

Review 10.  Ebolavirus Evolution: Past and Present.

Authors:  Marc-Antoine de La Vega; Derek Stein; Gary P Kobinger
Journal:  PLoS Pathog       Date:  2015-11-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.